<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234932</url>
  </required_header>
  <id_info>
    <org_study_id>19-12-005</org_study_id>
    <nct_id>NCT04234932</nct_id>
  </id_info>
  <brief_title>Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation</brief_title>
  <official_title>Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Incarnate Word</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of the Incarnate Word</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate changes in optical coherence tomography angiography of the optic nerve and macula
      following topical instillation of commercial preparations of netarsudil 0.02% ophthalmic
      solution.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripapillary capillary perfusion density</measure>
    <time_frame>90 minutes</time_frame>
    <description>Mean change in peripapillary capillary perfusion as assessed using optical coherence tomography angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular capillary perfusion density</measure>
    <time_frame>90 minutes</time_frame>
    <description>Mean change in macular capillary perfusion as assessed using optical coherence tomography angiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Netarsudil alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application of netarsudil 0.02%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Netarsudil plus latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical application of netarsudil 0.02% with latanoprost 0.005%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil Ophthalmic</intervention_name>
    <description>Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)</description>
    <arm_group_label>Netarsudil alone</arm_group_label>
    <arm_group_label>Netarsudil plus latanoprost</arm_group_label>
    <other_name>Latanoprost Ophthalmic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal ocular health

        Exclusion Criteria:

          -  Females who are or may be pregnant or who are nursing

          -  Uncontrolled hypertension

          -  Allergy to netarsudil or latanoprost
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary Jo Bilicek</last_name>
    <phone>210-805-3565</phone>
    <email>bilicek@uiwtx.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of the Incarnate Word</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana C Hagendorf, PhD</last_name>
      <phone>210-805-3036</phone>
      <email>wandless@uiwtx.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of the Incarnate Word</investigator_affiliation>
    <investigator_full_name>Richard Trevino, OD, FAAO</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

